Market
Novo Nordisk's revenue growth impact from Catalent acquisition in FY 2025
2
Resolution / Starting Odds
Growth above 10% • 25%
Growth 5-10% • 25%
Growth below 5% • 25%
No growth • 25%
Novo Nordisk's annual financial report
Story
Novo Nordisk Cleared to Acquire Three Catalent Manufacturing Sites for $CTLT Following FTC Approval
Dec 14, 2024, 08:49 AM
Novo Nordisk has received clearance to proceed with its acquisition of three manufacturing sites from Catalent, following the Federal Trade Commission's decision not to challenge the deal. This acquisition is part of a larger transaction involving Catalent and Novo Holdings, which has also met all regulatory closing conditions. The approval allows Novo Nordisk to enhance its manufacturing capabilities by integrating these sites, thereby strengthening its position in the pharmaceutical sector. The deal has been noted as significant given the current regulatory environment surrounding pharmaceutical acquisitions.
View original story
Similar markets
Decrease • 25%
Significantly increase • 25%
Slightly increase • 25%
No change • 25%
Less than 5% • 25%
10% to 15% • 25%
More than 15% • 25%
5% to 10% • 25%
Moderate increase • 25%
Decrease • 25%
No significant change • 25%
Significant increase • 25%
Below Top 20 • 25%
Top 10 • 25%
Top 20 • 25%
Top 5 • 25%
Match performance • 25%
Outperform significantly • 25%
Outperform slightly • 25%
Underperform • 25%
Below $100 • 25%
Above $150 • 25%
$126 to $150 • 25%
$100 to $125 • 25%
Partner with another company • 25%
Seek further trials • 25%
Submit for regulatory approval • 25%
Discontinue development • 25%